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Abstract
Objective: Dysferlin is a large transmembrane protein that functions in critical
processes of membrane repair and vesicle fusion. Dysferlin-deficiency due to
mutations in the dysferlin gene leads to muscular dystrophy (Miyoshi myopa-
thy (MM), limb girdle muscular dystrophy type 2B (LGMD2B), distal myopa-
thy with anterior tibial onset (DMAT)), typically with early adult onset. At least
416 pathogenic dysferlin mutations are known, but for approximately 17% of
patients, one or both of their pathogenic variants remain undefined following
standard exon sequencing methods that interrogate exons and nearby flanking
intronic regions but not the majority of intronic regions. Methods: We
sequenced RNA from myogenic cells to identify a novel dysferlin pathogenic
variant in two affected siblings that previously had only one disease-causing
variant identified. We designed antisense oligonucleotides (AONs) to bypass the
effects of this mutation on RNA splicing. Results: We identified a new patho-
genic point mutation deep within dysferlin intron 50i. This intronic variant
causes aberrant mRNA splicing and inclusion of an additional pseudoexon (PE,
we term PE50.1) within the mature dysferlin mRNA. PE50.1 inclusion alters
the protein sequence, causing premature translation termination. We identified
this mutation in 23 dysferlinopathy patients (seventeen families), revealing it to
be one of the more prevalent dysferlin mutations. We used AON-mediated
exon skipping to correct the aberrant PE50.1 splicing events in vitro, which
increased normal mRNA production and significantly restored dysferlin protein
expression. Interpretation: Deep intronic mutations can be a common underly-
ing cause of dysferlinopathy, and importantly, could be treatable with AON-
based exon-skipping strategies.
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Introduction
Dysferlinopathy is a degenerative muscle disease caused
by insufficient expression of dysferlin protein in skeletal
muscles.1,2 This is a recessively inherited disorder that
manifests in late teens to early adulthood as muscle weak-
ness due to muscle degeneration, which progressively
worsens, typically leading to significant loss of mobility.3
There is currently no cure for dysferlinopathy, and treat-
ment is limited to palliative care. Clinical trials have
recently begun to evaluate a virally mediated gene replace-
ment strategy to restore dysferlin expression, similar to
that described,4,5 but there remains a great need for novel
therapeutic approaches to treat this debilitating disease.
Dysferlin, a member of the ferlin family of Ca2+-
dependent phospholipid-binding proteins, is a large
(237 kDa) transmembrane protein important for mem-
brane repair, vesicle trafficking, and T-tubule struc-
ture.6–9 There are 14 known human isoforms of
dysferlin, generated by alternative exon splicing and the
use of two different promoters,10 with isoform 8 being
the predominant form in muscle. In addition to skeletal
muscle, dysferlin is expressed in other tissues, and dys-
ferlin-deficiency has been associated with immune cell
migration changes such as increased motility and
phagocytosis by blood monocytes.11–13 The dysferlin
expression level in blood monocytes can be used as a
diagnostic tool for dysferlinopathy.14–16 Clinically, how-
ever, the functional requirement for dysferlin is most
notable in skeletal muscle.
At least 416 different pathogenic dysferlin variants are
listed in the Universal Mutation Database (UMD-DYSF,
http://www.umd.be/DYSF/),17 most of these lying within
one of the 55 exons that are spliced together to form iso-
form 8 that is critical for muscle function. For approxi-
mately 17% of patients, a complete understanding of the
genetic lesions underlying their disease is lacking; at least
one of their pathogenic mutations has not been identified.
It is highly likely that these mutations lie somewhere
within dysferlin introns or areas other than exons that
regulate dysferlin expression. These gene regions are not
examined by standard exonic screening methods.
We recently identified one such pathogenic variant
deep within dysferlin intron 44i (c.4886 + 1249G>T) in
dysferlinopathy patients. This intronic variant induces
alternate splicing of the dysferlin transcript, allowing the
inclusion of a 177 bp pseudoexon (PE44.1) within the
mature transcript, resulting in an in-frame insertion of 59
amino acids within the C2F domain of the dysferlin pro-
tein.18 Here, we report the identification of another deep
intronic dysferlin variant, which also causes aberrant
mRNA splicing and pathogenic inclusion of a pseu-
doexon, this one leading to premature translation
termination. Antisense oligonucleotides (AONs) can be
used to inhibit this pseudoexon splicing event, restoring
normal mRNA splicing and dysferlin protein expression.
Methods
Patients
Samples used in this study (blood or skin biopsy samples)
were from patients clinically diagnosed as dysferlinopathy
patients (MM or LGMD2B). These patients exhibited
progressive limb muscle weakness beginning in adoles-
cence or early adulthood, elevated blood creatine kinase
levels indicating muscle damage, and demonstrated
reduced or absence of dysferlin protein expression in
muscle biopsies and/or blood monocyte cells when
screened as described.15,16 Patient materials were collected
in accordance with ethical guidelines and protocols
approved by the University of Massachusetts Medical
School Institutional Review Board, and similar review
boards at Emory University School of Medicine, Aix-Mar-
seille University ,or Institute of Genetic Medicine, New-
castle. For all of the patients described, only one or
neither of their pathogenic variants had been defined by
exon sequencing. The dysferlinopathy patients initially
screened, JF196 and JF23, are siblings participating in an
ongoing international “Clinical Outcome Study for Dys-
ferlinopathy”, a collaboration with the Jain Foundation
and Newcastle upon Tyne Hospitals. Patient skin fibrob-
lasts were obtained from the Newcastle upon Tyne Hospi-
tal Biobank. These patients are heterozygous for one
pathogenic dysferlin variant identified by exon sequencing
(c.5698_5699delAG; p.Ser1900GlnfsX14, stop codon in
exon 51, DYSF C2G domain), but their other pathogenic
allele had not been identified. Similarly, dysferlinopathy
patient TDM57 had only one pathogenic allele defined by
exon sequencing (c.2998T>C; p.Ser1000Pro, inner DysF
domain, predicted pathogenic, UMD-Predictor algorithm,
UMD-DYSF Universal Mutation Database). TDM57 skin
biopsy tissue was obtained via the Jain Foundation as part
of a diagnostic program at the Centre for Advanced
Molecular Diagnostics in Neuromuscular Disorders,
Mumbai, Maharashtra, India. TDM57 and other TDM
patients reported here (except TDM196 and TDM230)
were described previously16; all TDM patient genomic
DNA was sequenced at Emory University School of Medi-
cine as described.15 Additional patient genomic DNA
sequencing was performed at Aix-Marseille University or
Newcastle upon Tyne Hospitals. Fibroblasts from unre-
lated individuals served as DNA sequence analysis con-
trols (8597: dysferlinopathy patient with different
dysferlin mutations18; RB19895: ALS patient; NHDF-3:
normal).
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Cell culture
Skin biopsy samples were placed in culture dishes to
establish fibroblast cultures as previously described.18 We
also obtained normal adult human dermal fibroblasts (we
termed NHDF-2 and NHDF-3 cells) from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
Fibroblasts were transduced with lentivirus vectors carry-
ing tamoxifen-inducible MyoD to generate inducible
fibroblast-derived myogenic cells (iFDMs) as described.18
These cells proliferate as fibroblasts and can be induced
to differentiate into myotubes by treatment with 4-hydro-
xytamoxifen (TMX). TMX induces MyoD expression and
myotube formation when cells are cultured in low serum
differentiation medium (DM) (DMEM Glutamax with
pyruvate: Medium 199 (Gibco, Grand Island, NY, USA])
(3:1), 2% horse serum (HyClone, Logan, UT, USA),
20 mM HEPES, and 20 lg/mL insulin, 11 lg/mL trans-
ferrin, 1.3 lg/mL selenium (2X ITS, Gibco)).18
Nucleic acid purification
Genomic DNA was purified from cells using Gentra Pure-
gene (Qiagen, Valencia, CA, USA) reagents following
manufacturers’ protocols. RNA was purified from patient
and normal iFDM cells using TRIzol reagent (Life Tech-
nologies, Grand Island, NY, USA), digested with DNAse
(TURBO DNA-Free, Ambion, Austin, TX, USA) to
remove contaminating DNA, then RNA was reverse tran-
scribed (High Capacity cDNA Reverse Transcription Kit,
Applied Biosystems Foster City, CA, USA) using manu-
facturers protocols to generate cDNA for PCR analyses.
For all analyses, we used DYSF mRNA variant 8
(NM_003494.3), the predominant skeletal muscle isoform,
as the reference sequence.
RNA analysis
We used an RT-PCR approach and methods described
previously18 for PCR amplification and sequencing of the
complete dysferlin cDNA derived from myogenic cell
(iFDM cell) RNA. For this, 17 primer sets generating 450–
500 bp amplicons that tiled across the DYSF cDNA were
used as described18 to sequence and screen the cDNA for
mutations. Additionally, 12 primer sets (Table S1) that
tiled across DYSF intron 50i were used to sequence and
screen the patient genomic DNA for variants as previously
done for intron 44i.18 Additional primers (PE50.1-F and -
R) that can be used to sequence patient DNA for the
mutated sequence are also listed. M13 sequence tails were
added to primers to facilitate sequencing (M13-F, 50-GT
AAAACGACGGCCAGT -30 on forward primers; M13-R
50-CAGGAAACAGCTATGAC-30 on reverse primers).
Quantitative PCR (qPCR) was performed on cDNAs
(corresponding to 5 or 10 ng input RNA in reverse tran-
scription reactions) using DyNAmo HS SYBR Green
qPCR Kit reagents (Thermo Scientific) and a Bio-Rad
CFX384 C-1000 Touch Real-Time PCR Detection System
and conditions previously described.18 Primers that dis-
tinguish normal and PE50.1-containing DYSF mRNA
were used, along with primers that amplify a region of
exons 13–14, common to all DYSF splice forms, to quan-
titate the total DYSF mRNA expressed (i.e., 100% DYSF
expression) (Table S3). Primers for human beta-2-micro-
globulin (B2M, Bio-Rad) were used to normalize total
mRNA levels.
Antisense oligonucleotide treatment of cell
cultures
We designed antisense oligonucleotides (AONs) that tar-
get potential exonic splicing enhancer (ESE) sequences
within PE50.1 using Human Splicing Finder v.3.019 and
Rescue-ESE20 online tools. Blocking these ESEs with
AONs could inhibit the splicing of PE50.1 into mature
processed mRNAs, thereby leading to the synthesis of
normally spliced DYSF transcripts. We used three AONs
targeting PE50.1 (Table S2) along with a nonspecific
scrambled AON control (SCR) described previously.18
These AONs were synthesized as 20-O-methyl RNA with
full-length phosphorothioate backbones (Integrated DNA
Technologies, Coralville, IA, USA). iFDM cells derived
from patients JF196, JF23 and normal NHDF-2 fibroblasts
were allowed to differentiate for indicated lengths of time
to form myotubes. Cells were transfected with each AON
(600 nmol/L or other concentrations as indicated) (or TE
buffer as control) using Oligofectamine (Life Technolo-
gies) and the manufacturer’s protocol. After the indicated
times, RNA was extracted and evaluated by RT-PCR18
using primers 16-F and 15-R to amplify either the normal
DYSF sequence (88 bp) or the mutant version containing
PE50.1 (268 bp). Proteins were extracted from similar
cultures and evaluated on western blots using antibodies
against the dysferlin C-terminal region (NCL-Hamlet,
Leica, Buffalo Grove, IL, USA, 1/1000) and GAPDH
(G9545, Sigma, St. Louis, MO, USA, 1/1000) as
described.18 Protein expression levels were calculated from
western blot images using a Li-COR Odyssey infrared
imager and Image Studio Software (Li-COR).
Statistics
Statistical significance was evaluated using one-way analy-
sis of variance (ANOVA) with post hoc Tukey tests. For
this, we used Prism 5.0 statistical analysis software
(GraphPad Software, San Diego, CA, USA).
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Results
Identification of a deep intronic mutation in
DYSF intron 50i
Skin fibroblasts cultures from sibling dysferlinopathy
patients JF196 and JF23 were converted to myogenic
iFDM cell lines and induced to differentiate into myo-
tubes. RNA was then isolated and analyzed by RT-PCR to
determine the sequence of any dysferlin expressed in these
cells. We analyzed the dysferlin mRNA using PCR pri-
mers that generated overlapping amplicons tiling through
the entire mRNA. Two of the overlapping amplicon prod-
ucts from these patients were larger than products from
normal iFDM cells, indicating an insertion of extra
sequence within the dysferlin transcript in these patients
(Fig. 1). As shown in Figure 2A, sequence analysis of
these RT-PCR products revealed the insertion of 180 bp
of additional sequence between DYSF exons 50 and 51.
This sequence is present within intron 50i and is aber-
rantly spliced into the DYSF mRNA as a novel pseu-
doexon (PE) which we term pseudoexon 50.1 (PE50.1).
Sequence analysis of the remainder of the cDNA products
confirmed the other known pathogenic variant in these
patients (c.5698_5699delAG, exon 51) and revealed no
additional novel variants in the coding sequence. Inclu-
sion of PE50.1 in the mRNA transcript is predicted to
lead to insertion of 46 additional amino acids (aa) fol-
lowed by a stop codon encoded by the pseudoexon
sequence (Fig. 2A and C). In this aberrantly spliced DYSF
transcript that contains PE50.1, translation is predicted to
terminate within the DYSF C2G domain, losing the c-ter-
minus containing the transmembrane domain, critical for
DYSF function.
Further sequence analysis of genomic DNA from these
patient cells revealed that PE50.1 inclusion in the mRNA
transcripts is caused by a novel point mutation (c.5668-
824C>T) deep within intron 50i (Fig. S1). As shown in
Figure 2B, this point mutation creates a consensus splice
donor site that promotes the splicing of the 180 bp
PE50.1 sequence between exons 50 and 51. Additionally,
a consensus “YAG” splice acceptor sequence exists imme-
diately upstream of the PE50.1 sequence, along with a
pyrimidine-rich region and potential branch points as
predicted by Human Splicing Finder, all of which are
important for splicing (Fig. S2).
We analyzed genomic DNA and differentiated iFDM
cell cDNA derived from an unrelated dysferlinopathy
patient, TDM57. This patient also had only one known
pathogenic dysferlin variant identified (c.2998T>C).
Genomic DNA sequence analysis showed that this patient
also carries the c.5668-824C>T point mutation in intron
50i, and RT-PCR analysis of iFDM cell mRNA showed
the aberrant inclusion of PE50.1 in the mRNA of this
patient. Additional sequence variants present within
intron 50i of patients JF196, JF23, and TDM57 are sum-
marized in Table 1. Each of these variants are reported in
the dbSNP database and have no known pathogenicity.
Additional dysferlinopathy patients with
the intron 50i c.5668-824C>T mutation
We examined genomic DNA from additional dysfer-
linopathy patients that had only one or neither of their
pathogenic variants identified to determine if they carried
the 50i c.5668-824C>T intronic variant, including two
additional siblings of JF196 and JF23. As summarized in
Table 2, a total of 22 patients from 17 families were
found to carry this mutation, nine of them being
homozygous. As an indication of prevalence, this muta-
tion was found in 7/25 patients from India screened in
Atlanta (Dastur et al.), 3/32 patients screened in Mar-
seille; 8/56 patients screened in Newcastle.
Antisense oligonucleotides targeting PE50.1
restore production of normal DYSF mRNA
Given that aberrant splicing, caused by the c.5668-
824C>T intron 50i mutation, leads to inclusion of the
disruptive PE50.1 sequence, blocking this aberrant splic-
ing should restore normal DYSF RNA and protein. We
designed three antisense oligonucleotides targeting differ-
ent possible exonic splice enhancer (ESE) regions within
PE50.1 that could promote PE50.1 splicing into the
mature mRNA; targeting these ESEs with AONs would
prevent PE50.1 inclusion. RT-PCR analysis of patient’s
iFDM myotubes treated for 2 days with AONs reveals
Figure 1. Identification of the DYSF intron 50i mutation. RT-PCR of
differentiated iFDM cDNA from three patients (JF196, JF23, TDM57)
shows novel amplicons (arrow) in patient samples that are not in a
normal control sample (N). The novel amplicons were produced using
two primer sets (15F+R and 16F+R), whose amplicons overlap, but
not with any other sets (e.g., 17F+R), demonstrating additional
sequence within patient cDNA in this region. Each PCR product was
sequenced to identify the inserted sequence.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 645
J. A. Dominov et al. Pseudoexon Caused by Dysferlin Intronic Mutation
AB
C
Figure 2. Dysferlin mRNA splicing is altered in patients JF196 and JF23, leading to inclusion of pathogenic pseudoexon PE50.1. (A) cDNA
sequencing showed that patients JF196 and JF23 have a 180 nt insertion at the junction of exons 50 and 51, revealing the inclusion of a novel
pseudoexon, PE50.1, spliced into the coding sequence. PE50.1 encodes 46 additional amino acids followed by a stop codon. (B) DYSF intron 50i
genomic DNA sequencing showed patients are heterozygous for a point mutation (c.5668-824 C>T) (asterisk *) that creates a novel splice donor
consensus site at the 30 end of the PE50.1 sequence. In these heterozygous cells, both normal and mutant PE50.1-containing mRNA are
expressed, representing the alternative splice forms of the DYSF transcripts. The mRNA structure within DYSF exon 50 - intron 50i - exon 51 and
the site of the 50i mutation is shown (insert, upper right), along with the normal and mutant splicing patterns. Numbers along the RNA indicate
the size of each element in bp. (C) The normal and mutant DYSF mRNA splice products and proteins in the region of exons 40–55 are shown.
PE50.1 inclusion is predicted to result in a 46 amino acids insertion and premature translation termination within the C2G domain and loss of the
C-terminal transmembrane domain (TM), both of which are required for dysferlin function. The predicted truncated protein, if expressed, would
be 1935 aa rather than the normal 2081 aa.
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that AONs indeed inhibit the expression of the mutant
PE50.1 DYSF mRNA spliced form and restore higher
levels of the normal mRNA splice form that lacks PE50.1
(Fig. 3). The normal splice form could represent both
normal splicing (i.e., PE50.1 skipping) of the intron 50i
mutant allele as well as the normal splicing of the other
DYSF mutant allele expressed in these cells. The presence
and absence of PE50.1 in the mRNA transcripts were con-
firmed by sequencing the larger and smaller RT-PCR
products, respectively. These effects of AONs 1, 2, and 3
on PE50.1 skipping have been confirmed in independent
cell culture experiments (Two experiments for AON1, five
Table 2. Summary of patients with the new c.5668-824C>T mutation in intron 50i.
Patient ID Patient Origin Intron 50i Mutation Second DYSF Mutation Second DYSF Mutation Effects Laboratory Sibling Groups
JF23 UK c.5668-824C>T c.5698_5699delAG p.Ser1900GlnfsX14
Stop at p.1913, C2 domain G
1, 5 A
JF196 UK c.5668-824C>T c.5698_5699delAG p.Ser1900GlnfsX14
Stop at p.1913, C2 domain G
1, 5 A
IGM7 UK c.5668-824C>T c.5698_5699delAG p.Ser1900GlnfsX14
Stop at p.1913, C2 domain G
5 A
IGM8 UK c.5668-824C>T c.5698_5699delAG p.Ser1900GlnfsX14
Stop at p.1913, C2 domain G
5 A
JF404 USA c.5668-824C>T c.2997G>T p.Trp999Cys
Missense, DysF domain
2, 4 B
JF1729 USA c.5668-824C>T c.2997G>T p.Trp999Cys
Missense, DysF domain
2 B
JF4228 USA c.5668-824C>T c.5668-824C>T 2
TDM48 India c.5668-824C>T c.5668-824C>T 3
TDM57 India c.5668-824C>T c.2998T>C p.Ser1000Pro
Missense, inner DysF domain
1, 3 C
TDM58 India c.5668-824C>T c.2998T>C p.Ser1000Pro
Missense, DysF domain
3 C
TDM63 India c.5668-824C>T c.5668-824C>T 3
TDM93 India c.5668-824C>T c.5668-824C>T 3
TDM180 India c.5668-824C>T c.5668-824C>T 3
TDM182 India c.5668-824C>T c.5668-824C>T 3
TDM196 India c.5668-824C>T c.5668-824C>T 2
TDM230 India c.5668-824C>T c.1911C>G p.Tyr637X
Stop at p.637
2
F1-170-1-2 France c.5668-824C>T c.855+1delG p.285
Exon 8 +1 delG, splicing
C2 domain B
4 D
F1-170-2-2 France c.5668-824C>T c.855+1delG p.285
Exon 8 +1 delG, splicing
C2 domain B
4 D
F1-436-1-0 India c.5668-824C>T c.5668-824C>T 4
IGM1 UK c.5668-824C>T c.1911c>G p.Tyr637X
Stop at p.637
5
IGM2 UK c.5668-824C>T c.5668-824C>T 5
IGM3 UK c.5668-824C>T c.2434dup p.811
Ferlin domain B
5
IGM4 UK c.5668-824C>T c.937+1G>A p.312
Exon 10 +1G>A, splicing
Ferlin domain
5
Initial patients found to carry the mutation are in italic type. The intron 50i mutation is highlighted in bold. Siblings that are members of four
families, A, B, C and D are indicated in the last column. Laboratory that identified the patient’s mutation:
1 Univ. Massachusetts Medical School, Worcester.
2 Emory Univ. School of Medicine, Atlanta.
3 Emory Univ. School of Medicine, Atlanta, described in Dastur et al. 2017.
4 Marseille Medical Genetics, Aix-Marseille University, Marseille.
5 Institute of Genetic Medicine, Newcastle.
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for AON2, four for AON3), and the effects observed in
cells from all three patients (JF196, TDM57, JF23;
Figs. 3–5).
As shown in Figure 4A, a decrease in the mutant
PE50.1 mRNA splice form is observed across a range of
AON2 concentrations tested in both JF196 and TDM57
patient cells, representing two different families with this
mutation. Quantitation of this effect is shown in Fig-
ure 4B. In a separate experiment, a broader AON concen-
tration range was used to evaluate the relative
effectiveness of AONS 1, 2, and 3 on PE50.1 skipping in
iFDM cells from three patients (JF196, JF23, and TDM57)
and a normal control (Fig. 5). In all three patient cell
lines, AON2 was most effective in reducing the expression
of the mutant PE50.1 splice form (i.e., inducing PE50.1
skipping) and increasing levels of the normal splice form.
AON3 was less effective and AON1 least effective in alter-
ing mutant PE50.1 mRNA levels. In all three cell lines, as
little as 20 nmol/L AON2 significantly reduced the
mutant PE50.1 mRNA levels compared with TE-treated
controls (Fig. 5, left panels). AON3 significantly reduced
mutant PE50.1 expression at 80 nmol/L for two of the
three cell lines and at 160 nmol/L, for the third, while
AON1 significantly reduced expression in only one line at
80 nM, and at 160–320 nmol/L for the other lines. A
similar trend in relative potency of the three AONs was
observed for the increase in normal transcripts (Fig. 5
right panels). Consistent with previous experiments, a
scrambled AON control (SCR) did not affect mutant
PE50.1 mRNA in any cells, and no PE50.1 mRNA was
detected in normal cells.
The relative proportion of the mutant PE50.1 mRNA
splice form expressed in patient cells was calculated using
pooled control (TE and no treatment cells) RT-qPCR
data from Figures 4 and 5 (patient JF196 n = 6, patient
JF23 n = 3, patient TDM57 n = 5 cultures). PCR ampli-
cons that span DYSF exons 13–14 were used to quantify
total DYSF expression in each sample, which overall is
reduced to similar extents in each of the mutant lines
compared to normal cells: patients JF196, JF23, and TDM
57 DYSF mRNA levels are ~38%, ~31%, and ~43% that
of normal NHDF2 cells, respectively. Mutant PE50.1 tran-
scripts represent ~26.9  3.4%, 20.2  1%, and
~11.8  3.0% (mean  SD) of total DYSF transcripts in
JF196, JF23, and TDM57 cells, respectively. It is not clear
if this variation in the proportion of mutant transcripts
reflects true differences in PE50.1 expression between
patients or simply cell line variation. Quantitation of
PE50.1 expression in muscle tissue would more accurately
address mutant PE50.1 mRNA expression variation
among patients with the intron 50i mutation, but unfor-
tunately, muscle tissues were not available from any
A
B
Figure 3. Antisense oligonucleotide-mediated skipping of PE50.1 in patient iFDM cells. (A) Pre-mRNA DYSF transcript and AON1, AON2 and
AON3 (Table S2), which target potential exonic splicing enhancers in PE50.1 as shown. Primers in exon 50 (16F) and 51(15R) amplify cDNAs to
distinguish normal mRNA transcripts (88 bp product containing exon 50 + 51) from mutant PE50.1 transcripts (268 bp product containing exon
50 + PE50.1 + 51). (B) RT-PCR analysis of mRNA splicing. Patient JF196 iFDM cells treated with AON1, AON2 and AON3 (600 nmol/L, duplicate
cultures for each) expressed reduced amounts of PE50.1 mutant mRNA and higher normal DYSF mRNA compared with a non-specific scrambled
(SCR, 600 nmol/L) AON-treated, TE-treated, or no treatment cells. Normal (NHDF-2) iFDMs only expressed normal DYSF transcripts. iFDMs were
allowed to differentiate in DM for 6 days then treated with AONs in DM for an additional 2 days. (-RT), no reverse transcriptase; H2O, no RNA
used in RT reactions.
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patients in this study. The relative abundance of mutant
PE50.1 mRNA could reflect a combination of i) the effi-
ciencies of mutant and normal splicing reactions that
generate mutant and normal mRNA from pre-mRNA car-
rying the intron 50i mutation, ii) the rate of mRNA
decay, likely accelerated by stop codons such as that
encoded in PE50.1 (nonsense-mediated decay), and iii)
the production and stability of transcripts derived from
the patients’ other mutant alleles. For patients JF196 and
JF23, the second DYSF mutation creates a stop codon at
p.1913, while patient TDM57 has a missense mutation
(p.Ser1000Pro) (Table 2). These second mutations, com-
bined with the intron 50i mutation in these patients, lead
to the overall reduction in DYSF mRNA expression.
Antisense oligonucleotide treatment for 3 days (fol-
lowed by 4 days without AONs) also restored DYSF pro-
tein expression to levels similar to that in normal
myotubes (Fig. 6), likely as a result of the higher amounts
of normally spliced transcripts induced by PE50.1 skip-
ping. The premature translational stop codon within
PE50.1 likely leads to nonsense-mediated mRNA decay,
whereby mRNA carrying a premature stop codon is tran-
scribed and spliced but degraded during the translation
process,21 leading to reduced mRNA levels (typically
detectable using sensitive RT-PCR methods) along with
aborted protein synthesis. The overall reduced levels of
RT-PCR products we observed in untreated or control-
treated patient cells compared with normal cells (de-
scribed above) are consistent with this. It is unlikely that
the mutation leads to significant synthesis of a truncated
protein (as predicted from the sequence, shown in
Fig. 2C) because we did not detect the expression of a
shorter DYSF protein on western blots using an antibody
specific to the DYSF N-terminal region (Abcam JAI-1-49-
3, Romeo, data not shown). However, our current data
cannot rule out the possibility of low level expression of a
truncated, possible unstable protein, or possibly low levels
of a toxic protein species. Studies overexpressing the trun-
cated protein form could determine if it affects muscle
cells, which could have a bearing on AON therapeutic
A
B
Figure 4. Antisense oligonucleotides at a variety of concentrations induce skipping of PE50.1 in patient iFDM cells. (A) Using experimental
conditions in Figure 3, iFDM cells (duplicate cultures for each treatment) from patients JF196, TDM57 and a normal (NHDF-2) control were
treated with AON2 or scrambled (SCR) control AONs at the concentrations shown or TE alone. In both patient cell lines, AON2 treatment at each
concentration tested reduced PE50.1 mutant mRNA expression compared with SCR or TE controls. (B) Quantitative RT-PCR analysis of the RNAs in
panel A shows that treatment of patient iFDMs with AON2 significantly reduces the expression of the mutant transcripts compared to SCR and TE
controls (*P < 0.05) (gray bars, mutant transcripts; black bars, normal transcripts; mean  SD). The relative expression of each form is calculated
using the amplification of a PCR product spanning the exon 13-14 junction as representative of 100% DYSF expression.
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strategies because it would be important to block the
production of a toxic protein production as much as
possible.
Discussion
Using myogenic cells derived from patient skin fibrob-
lasts, we identified a novel point mutation deep within
DYSF intron 50i (c.5668-824C>T) that causes aberrant
dysferlin mRNA splicing and the inclusion of a patho-
genic pseudoexon (PE50.1) in dysferlin mRNA. This is
the second such deep intronic pseudoexon-generating
point mutation we have identified using this approach;
the previous one was identified within DYSF intron 44i
(PE44.1).18 Initially identified in two siblings with dysfer-
linopathy (JF196, JF23), we found a total of 23 patients
from 17 families that carry this intron 50i mutation, mak-
ing it one of the more prevalent pathogenic DYSF muta-
tions when compared with those in the Universal
Mutation Database (UMD-DYSF, http://www.umd.be/
DYSF/).17
Known pathogenic variants in genes are typically iden-
tified by screening patients’ genomic DNA using exon
sequencing methods that interrogate the coding regions
and intronic sequences near the exon junctions. Whole
genome sequencing can identify sequence variants in
other noncoding regions (e.g., introns, promoters, and
untranslated regions), but the pathological significance of
these might not be directly evident. We find that screen-
ing RNA from patient cells (i.e., iFDM cells derived from
dysferlinopathy patients) for sequence variations is a use-
ful approach to identifying mutations that alter the pro-
tein coding sequence. Our current studies, as with our
previous work,18 demonstrate that point mutations deep
within dysferlin introns can alter splicing and drive the
inclusion of pathogenic pseudoexons.
Pseudoexons such as these, caused by mutations that
introduce novel splice donor or acceptor sites, or affect
Figure 5. AON2 is more effective than AON1 and AON3 for inducing PE50.1 skipping in all three patient cell lines. Using experimental conditions
and analyses as in Figures 3 and 4, iFDM cells from patients JF196, JF23, and TDM57 and a normal (NHDF-2) control were treated with AON1,
AON2 or AON3 at the concentrations show, scrambled control AONs (SCR 320 nmol/L), TE (TE 0) or not treated (0). RT-Q-PCR shows that in all
three cell lines, each of the AONs at the highest concentration can significantly reduce the expression of the mutant transcripts compared to TE
controls (*P < 0.05). AON2 shows significant effects on PE50.1 expression at lower concentrations than other AONs in all three cell lines. Data
indicate the relative effectiveness for inducing PE50.1 skipping is AON2 > AON3 > AON1 (gray bars, mutant transcripts; black bars, normal
transcripts; duplicate cultures for each treatment (mean  SD) except for four samples (marked #) in which a single culture was used due to
sample loss or poor RNA quality.
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exonic splicing enhancer interactions, have been identified
in many other genes (reviewed in22), among them DMD,
the gene for dystrophin, causing Duchenne muscular dys-
trophy (reviewed in [23]), and recently COL6A1, causing
collagen VI-related dystrophy.24 Given that many dysfer-
linopathy patients do not have both of their pathogenic
variants identified through standard exome sequencing, it
is likely that identification of other novel DYSF mutations
in noncoding regions could be identified by analysis of
RNA sequence variations. This could be done either using
our approach of direct sequencing of RT-PCR products,
or through RNAseq analysis, recently used to characterize
splicing patterns of normal human dystrophin tran-
scripts25 and to identify splicing abnormalities in this and
a number of other muscle disease-related genes.24,26
While our studies used RNA from myogenic cells
(iFDMs) derived from skin biopsy fibroblasts, future diag-
nostic pipelines could potentially use blood monocytes,
B
A
Figure 6. Treatment of patient iFDM cells with AON2 and AON3 directed to PE50.1 induces dysferlin protein expression. JF196 iFDM cells
(duplicate cultures) were allowed to differentiate in DM for 6 days then treated with AONs in DM (or TE buffer as controls) for 3 days, and cells
collected for protein analysis 7 days after AON addition. (A) Western blots show that after 7 days of AON3 treatment (4 days after AON removal)
there was a dramatic increase in DYSF protein expression compared with control cells. GAPDH expression served as a control for protein loading
(5 lg protein/lane). Protein levels in normal control iFDM cultures are not affected by AON treatments. (B) Quantitation of DYSF protein expressed
in panel A, normalized to GAPDH levels and shown relative to normal cells treated with TE. The mean relative DYSF expression in patient cells
was significantly higher in both AON2- and AON3-treated cells compared with SCR- or TE-treated controls (P < 0.05, one-way ANOVA, Tukey’s
Multiple Comparison Test).
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which also express dysferlin.14 Analysis of dysferlin pro-
tein expression in monocytes is a useful diagnostic tool
for primary dysferlinopathies.15,16 Different isoforms of
dysferlin are expressed in blood cells compared with mus-
cle,10 but these differences involve variable splicing of
only 3 of the 55 dysferlin exons (5a, 17, 40a), using two
different promoters. Therefore, the majority of exon splic-
ing events are likely to be common between blood and
muscle cells; blood cell RNA screening could detect aber-
rant spicing events in a large proportion of the DYSF
transcripts. In preliminary studies (not shown), we have
generated amplicons that span the DYSF transcript using
RNA from blood cells and our overlapping primer sets.
RNA sequence analysis of blood monocytes could provide
a less invasive and more cost-effective primary screen for
elusive pathogenic variants not identified by standard
exon sequencing methods.
The aberrant, pathogenic inclusion of a pseudoexon in
the mature transcript of a gene, such as DYSF PE50.1,
provides an ideal target for AON-mediated exon-skipping
therapeutics. As with our previous studies targeting the
pathogenic pseudoexon DYSF PE44.1,18 treatment of cells
with AONs targeting PE50.1 induces skipping of this
pseudoexon, synthesis of the normal DYSF mRNA tran-
script, and the restoration of near normal DYSF protein
levels. The minimum level of DYSF protein required for
normal muscle function has not been determined, but in
one documented case a 70-year-old patient with only
mild dystrophic symptoms was found to express dysferlin
at approximately 10% of normal levels, indicating that
this is sufficient for significant muscle function. This
patient carried one severe DYSF mutation that produced
no protein and a second intronic DYSF mutation that
altered splicing, causing omission of exon 32 but main-
taining the reading frame, possibly generating a partially
functional protein.27 Data suggested that the DYSF pro-
tein expressed was largely from the aberrantly spliced
mRNA, but authors noted that expression of the normally
spliced form could not be excluded. It will be important
to evaluate the efficacy of AON treatments in altering the
expression of DYSF protein in vivo, for example in
homozygous mutant animal models expressing DYSF
PE50.1, to determine the level of protein achieved in dis-
eased muscle tissue, the kinetics and efficiency of this
process, and the therapeutic impact on disease progres-
sion and muscle restoration at later stages of disease.
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Figure S1. Analysis of genomic DNA from patients JF196,
JF23 and TDM57 revealed that they are heterozygous for
the c.5668-824C>T mutation deep within DYSF intron
50i. Genomic DNAs from patients’ fibroblasts were
amplified and sequenced using primer sets that tiled
through 50i (Supplementary Table 1), revealing this
mutation in these dysferlinopathy patient cells but not in
fibroblasts from unrelated patients (8597: patient with
other dysferlin mutations18; RB19895: ALS patient) or
normal human dermal fibroblasts (NHDF-3). Samples
shown here were amplified using primers PE50.1-F and
PE50.1-R then sequenced in the forward (F) and reverse
(R) directions as indicated.
Figure S2. The intronic sequence upstream of pseu-
doexon PE50.1 contains additional consensus sites
required for mRNA splicing. These include a splice accep-
tor sequence (ag) at the 50 end of PE50.1, an adjacent
pyrimidine-rich region and two potential lariat branch
point consensus sequences (underlined) that could be
used to promote splicing. These sequences, in the pre-
sence of c.5668-824 C>T mutation, likely allow PE50.1 to
be spliced between exons 50 and 51.
Table S1. Primers (forward (F) and reverse (R)) used to
generate overlapping amplicons that span dysferlin intron
50i, and an additional primer set (PE50.1-F, PE50.1-R)
useful for genotyping.
Table S2. AONs targeting human exonic splicing enhan-
cer sequences (ESE) in DYSF PE50.1. AONs for in vitro
studies are 20-O-methyl RNA with full-length phospho-
rothioate backbones.
Table S3. Primers (forward (F) and reverse (R)) used in
quantitative PCR assays to analyze DYSF mRNA expres-
sion.
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